Document:

Exhibit 10.1

 

BOARD REPRESENTATION AND STANDSTILL
AGREEMENT

 

THIS BOARD REPRESENTATION
AND STANDSTILL AGREEMENT (this “Agreement”), dated as of August 29, 2016, is entered into by and between (i)
Concurrent Computer Corporation, a Delaware corporation (the “Company”), on the one hand, and (ii) JDS1, LLC,
a Delaware limited liability company (the “Investor”), Julian Singer, in his individual capacity (the “Investor
Affiliate,” and together with the Investor, the Investor Affiliate, and the Affiliates and Associates of each of the
foregoing, the “Investor Group”), and Wayne Barr in his individual capacity (the “Nominee”),
on the other hand.

 

WHEREAS, as of the
date hereof, the members of the Investor Group, collectively, beneficially own, in the aggregate, the number of shares of the Company’s
common stock, par value $0.01 per share (the “Common Stock”), set forth on Schedule A; and

 

WHEREAS, the Company,
the Investor Group and the Nominee desire to undertake the actions and agreements contained herein.

 

NOW, THEREFORE, in
consideration of the foregoing and the mutual promises, representations, warranties, respective covenants and agreements of the
parties contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged
by each of the parties hereto, the parties hereto, intending to be legally bound hereby, agree as follows:

 

ARTICLE
1

DEFINITIONS

 

The following terms, as used in this Agreement,
have the following meanings:

 

		(a)	the terms “Affiliate” and “Associate” have the respective
meanings given to such terms in Rule 12b-2 promulgated by the Securities and Exchange Commission (the “SEC”)
under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall include Persons who become
Affiliates or Associates of any Person subsequent to the date of this Agreement; provided, however, that for purposes
of this Agreement, (a) the members of the Investor Group and their Affiliates and Associates, on the one hand, and the Company
and its Affiliates and Associates, on the other, shall not be deemed to be “Affiliates” or “Associates”
of one another and (b) any business entity of which the Nominee is a member of the board of directors (or similar governing body)
shall not be deemed to be an “Affiliate” of the Investor solely due to such relationship;

 

		(b)	the terms “beneficial owner” and “beneficially own” have
the respective meanings given to such terms in Rule 13d-3 promulgated by the SEC under the Exchange Act;

 

		(c)	the term “Derivative Instrument” means any profits interest, option, warrant,
convertible security, stock appreciation right, or similar right with an exercise or conversion privilege or a settlement payment
or mechanism at a price related to any class or series of securities of the Company or with a value derived in whole or in part
from the value of any class or series of securities of the Company or any derivative or synthetic arrangement having characteristics
of a long position in any class or series of securities of the Company, whether or not such instrument or right shall be subject
to settlement in the underlying class or series of securities of the Company, or otherwise;

 

     

     

    

 

		(d)	the terms “Person” or “Persons” mean any individual, corporation
(including not-for-profit), general or limited partnership, limited liability or unlimited liability company, joint venture, estate,
trust, association, organization or other entity of any kind or nature;

 

		(e)	the term “Plan” means the Company’s Tax Asset Preservation Plan, dated
March 1, 2016; and

 

		(f)	the term “Voting Securities” means Common Stock and any other securities of
the Company entitled to vote in the election of directors of the Company, or securities convertible into, or exercisable or exchangeable
for Common Stock or such other securities.

 

ARTICLE
2

BOARD REPRESENTATION

 

		2.1	Director Nominee

 

		(a)	Having considered the request of the Investors that the Nominee be appointed to the Company’s
board of directors (the “Board”), and having received the consent of the Nominee to act as a director of the
Company, the Nominating Committee of the Board (the “Nominating Committee”) has reviewed such nomination and
has recommended the appointment of the Nominee as a director of the Company on the terms set forth in this Agreement. Based upon
such recommendation, concurrent with the execution and delivery of this Agreement, the Board has, as of this date, (i) elected
the Nominee as a director of the Company, to serve until the annual meeting of stockholders of the Company to be held during the
2016 calendar year (the “2016 Meeting”) on the terms set out in this Agreement, (ii) accepted the resignation
of C. Shelton James as a director of the Company, effective conditioned upon the appointment of the Nominee to the Board, and (iii)
subject to compliance by each member of the Investor Group and the Nominee with all of the terms of this Agreement and the Nominee
continuing to satisfy all of the Conditions (as defined herein), determined to nominate the Nominee for election as a director
of the Company and recommend, support and solicit proxies in favor of his election by stockholders at the 2016 Meeting in the same
manner as the Company Nominees (as defined herein). If the Nominee is elected by the Company’s stockholders to serve as directors
of the Company at the 2016 Meeting, then subject to compliance by each member of the Investor Group and the Nominee with all of
the terms of this Agreement and the Nominee continuing to satisfy all of the Conditions, the Nominee shall serve until the annual
meeting of stockholders of the Company to be held during the 2017 calendar year (including any adjournment or postponement thereof)
(the “2017 Meeting”), or until his earlier death, resignation, disqualification or removal. In addition, in
connection with the nomination of the Nominee for election as a director of the Company at the 2016 Meeting, each party to this
Agreement hereby acknowledges and agrees that the slate of nominees for election as directors of the Company at the 2016 Meeting
will consist of (i) the Nominee (Wayne Barr) and (ii) Derek Elder, Steve G. Nussrallah, Charles Blackmon, Larry Enterline, Dilip
Singh and Robert Pons (such individuals in this clause (ii) being the “Company Nominees”).

 

    	 	2	 

     

    

 

		(b)	The Company acknowledges that the Nominee has satisfied all of the Conditions to the Nominee’s
nomination for election as a director of the Company at the 2016 Meeting under the Company’s Bylaws, policies and procedures,
and the Nominee and each member of the Investor Group have provided to the Company the information that is required to be disclosed
for a candidate for director in a proxy statement under the federal securities laws or applicable rules and regulations of The
Nasdaq Stock Market.

 

		(c)	Promptly following Mr. Barr’s appointment to the Board, the Board agrees to appoint Mr. Barr
as (i) a member of the Nominating Committee (such that the Nominating Committee will be comprised of Steve G. Nussrallah, Charles
Blackmon and Wayne Barr), and (ii) a member of the special committee formed in connection with the exploration of strategic alternatives
(the “Special Committee”). The Company also acknowledges that the Compensation Committee will be comprised of
Charles Blackmon, Larry Enterline and Robert Pons. Until the Termination Date (as defined herein), one of Mr. Barr, Mr. Singh and
Mr. Pons (collectively, including any replacement nominee designated by the Investor pursuant to Section 2.1(e)(i), the “Designated
Directors”) will be a member of the Nominating Committee, one of the Designated Directors will be a member of the Compensation
Committee and the Nominee will be a member of the Special Committee. Notwithstanding the foregoing, the Board may change the composition
of the Special Committee or request that the Nominee appointed to the Special Committee recuse themselves from the consideration
of certain matters if the Board reasonably determines based on the advice of counsel that the Nominee’s participation in
matters considered by the Special Committee would be inconsistent with the fiduciary duties of the Board or if the Nominee has
a conflict of interest regarding matter(s) considered by the Special Committee unrelated to the fact that the Nominee was added
to the Board at the request of the Investor Group.

 

		(d)	Upon becoming a director of the Company, and at all times while serving as a director of the Company,
the Nominee shall: (i) comply with all reasonably customary policies, procedures, processes, codes, rules, standards and guidelines
generally applicable to members of the Board, including, without limitation, the Company’s code of conduct, Insider Trading
Compliance Policy (the “Trading Policy”) and corporate governance guidelines; (ii) keep confidential and not
publicly disclose discussions and matters considered in meetings of the Board and committees of the Board, unless previously disclosed
publicly by the Company; (iii) be compensated for his service as a director and will be reimbursed for his expenses on the same
basis as all other non-employee directors of the Company; (iv) be granted equity-based compensation and other benefits on the same
basis as all other non-employee directors of the Company; and (v) be entitled to the same rights of indemnification and directors’
and officers’ liability insurance coverage as the other non-employee directors of the Company as such rights may exist from
time to time.

 

    	 	3	 

     

    

 

		(e)	The Company, each member of the Investor Group and the Nominee acknowledges and agrees that:

 

		(i)	if, prior to the Termination Date, one of the Designated Directors is or otherwise becomes unable
to serve as a director of the Company due to death, disability, conflict of interest or a legitimate personal hardship (or if the
Nominee shall fail to satisfy the Conditions), the Investor shall have the right to designate another individual for appointment
as a replacement nominee, provided that any replacement nominee meets all independence and other standards under the applicable
rules of The Nasdaq Stock Market and the SEC and the applicable provisions of the Exchange Act, has the relevant financial and
business experience to fill the resulting vacancy and shall be subject to the reasonable approval of the Nominating Committee in
good faith after exercising its fiduciary duties in accordance with the Company’s corporate governance guidelines and the
charter of the Nominating Committee, (and, any such individual shall be considered as a “Nominee” for all purposes
under this Agreement), provided further, however, that such replacement nominee shall be required to sign a joinder
agreement agreeing to be bound by the terms and provisions of this Agreement;

 

		(ii)	the Company shall be under no obligation to nominate the Nominee or any other designee of the Investor
for election to the Board at the 2017 Meeting; and

 

		(iii)	if, prior to a Company Nominee’s election to the Board at the 2016 Meeting, a Company Nominee
is or otherwise becomes unable or unwilling to serve as a director of the Company (other than where the Company Nominee is also
a Designated Director and such Designated Director is unable to serve due to any of the circumstances set forth in Section 2.1(e)(i))
the Company shall have the right to designate another individual for appointment as a replacement nominee, subject to the reasonable
approval of the Investor (and, any such individual shall be considered as a “Company Nominee” for all purposes under
this Agreement).

 

    	 	4	 

     

    

 

		(f)	The Company agrees that, without the Investor’s written consent, from the date of this Agreement
until one day after the 2017 Meeting, the size of the Board shall be fixed at seven directors. Until the Termination Date, the
Company agrees that it will not form new committees or subcommittees of the Board to which significant decision-making authority
is delegated that do not have the Nominee as a member, unless the Board reasonably determines based on advice of counsel that a
failure to do so would be inconsistent with the fiduciary duties of the Board.

 

		(g)	The Investor hereby irrevocably withdraws its letter dated July 27, 2016 (as supplemented on July
29, 2016) providing notice to the Company of its intention to nominate certain individuals for election as directors of the Company
at the 2016 Meeting (the “JDS1 Nomination”), and the Investor Group shall immediately cease, and shall cause
each of its Affiliates to immediately cease, all efforts, direct or indirect, in furtherance of the JDS1 Nomination and any related
solicitation in connection with the JDS1 Nomination.

 

		2.2	Conditions

 

		(a)	Notwithstanding anything to the contrary in this Agreement, the Nominee shall, as a condition to
being nominated and at all times while serving on the Board, satisfy the following conditions as reasonably determined by the Board
(such conditions referred to as the “Conditions”);

 

		(i)	meet all independence and other standards under applicable rules of The Nasdaq Stock Market and
the SEC and applicable provisions of the Exchange Act; and

 

		(ii)	be qualified to serve as a director under Delaware law.

 

		(b)	The Nominee shall promptly advise the Chairperson of the Nominating Committee in writing in the
event that the Nominee ceases to satisfy any of the Conditions.

 

		(c)	Notwithstanding anything to the contrary in this Agreement, if at any time while the Nominee serves
as a director of the Company (i) the Nominee ceases to satisfy any of the Conditions or breaches any of his obligations under Section 2.1(d),
or (ii) if this Agreement is terminated by the Company pursuant to Section 5.13(b) or 5.13(c), the Nominee shall
resign from the Board and all applicable Board committees immediately, and the Nominee shall deliver his written resignation to
the Board forthwith.

 

		2.3	Nature of Rights

 

Notwithstanding anything
to the contrary in this Agreement, the rights and privileges set forth in this Article 2 shall be personal to each
member of the Investor Group and the Nominee and may not be transferred or assigned to any Person.

 

    	 	5	 

     

    

 

ARTICLE
3

REPRESENTATIONS AND WARRANTIES

 

		3.1	Representations and Warranties of the Investor and
the Investor Affiliate

 

The Investor and the
Investor Affiliate, jointly and severally, represent and warrant to the Company that:

 

		(a)	the Investor is duly organized, validly existing and in good standing under the laws of its jurisdiction
of organization (if applicable) and has all requisite power and authority to execute and deliver this Agreement;

 

		(b)	this Agreement has been duly executed and delivered by each of the Investor, the Investor Affiliate
and the Nominee;

 

		(c)	this Agreement constitutes the valid and binding agreement of the Investor, the Investor Affiliate
and the Nominee, enforceable against the Investor, the Investor Affiliate and the Nominee in accordance with its terms, except
as may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization moratorium, and similar laws relating to or
affecting creditors’ rights generally and general equitable principles (whether considered in a proceeding in equity or at
law), in each case now or hereafter in effect;

 

		(d)	as of the date of this Agreement, (i) the members of the Investor Group, collectively, beneficially
own, in the aggregate, the number of shares of Common Stock set forth on Schedule A, and (ii) such shares of Common Stock
constitutes all of the Voting Securities beneficially owned by the members of the Investor Group;

 

		(e)	this Agreement will not result in a violation of any terms or provisions of any agreements to which
such person is a party or by which such party may otherwise be bound or of any law, rule, license, regulation, judgment, order
or decree governing or affecting such party; and

 

		(f)	except as set forth on Schedule A, no member of the Investor Group, directly or indirectly
(i) owns beneficially or of record any Derivative Instruments, (ii) beneficially owns, or has any rights or options, or is party
to any proxy, contact, arrangement, agreement or understanding to acquire or vote, any shares of Common Stock or Derivative Instruments
or (iii) beneficially owns, or has any rights or options, or is party to any proxy, contact, arrangement, agreement or understanding
to acquire any debt securities of the Company.

 

    	 	6	 

     

    

 

		3.2	Representations and Warranties of the Company

 

The Company represents and warrants to the
Investor that:

 

		(a)	the Company is duly incorporated, validly existing and in good standing under the laws of the State
of Delaware and has all requisite corporate power and authority to execute and deliver this Agreement;

 

		(b)	this Agreement has been duly executed and delivered by the Company;

 

		(c)	this Agreement will not result in a violation of any terms or provisions of any agreements to which
such person is a party or by which such person may otherwise be bound or of any law, rule, license, regulation, judgment, order
or decree governing or affecting such person; and

 

		(d)	this Agreement constitutes the valid and binding agreement of the Company, enforceable against
the Company in accordance with its terms, except as may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium, and similar laws relating to or affecting creditors’ rights generally and general equitable principles (whether
considered in a proceeding in equity or at law), in each case now or hereafter in effect.

 

ARTICLE
4

COVENANTS

 

		4.1	Covenants of the Investor Group

 

		(a)	Except as otherwise requested by the Board, the Investor and the Investor Affiliate shall cause
all Voting Securities beneficially owned, directly or indirectly, by each of the Investor and the Investor Affiliate and any other
members of the Investor Group, or over which any of them exercise control or direction, to be present for quorum purposes and to
be voted, at the 2016 Meeting in accordance with the Board’s recommendation with respect to (i) each of the Company’s
nominees for election to the Board and (ii) any amendment to the Company’s certificate of incorporation proposed by the Company
providing for limitations on the ownership of the outstanding shares of common stock of the Company to preserve the Company’s
net operating losses (the “Charter Amendment”), provided that any such Charter Amendment does not prohibit the
Investor, Investor Affiliate, or any of their respective Affiliates or Associates from beneficially owning shares of the common
stock of the Company in an amount that is less than or equal to 19.9% of the outstanding shares of Common Stock of the Company
if the beneficial ownership of such Common Stock by the Investor, the Investor Affiliate, or any of their respective Affiliates
or Associates would reasonably be expected to actually limit the Company’s ability to utilize the NOLs (as defined in the
Plan); and

 

		(b)	From the date of this agreement until the Termination Date, no member of the Investor Group shall,
unless specifically requested or authorized in writing by a resolution of a majority of the directors of the Company (not including
the Nominee), directly or indirectly, in any manner, alone or in concert with others:

 

    	 	7	 

     

    

 

		(i)	except as already in effect as of the date hereof and previously disclosed in the Schedule 13D
with respect to the Company filed with the SEC by the Investor on February 16, 2016, as amended (the “Investor 13D”),
form, join, encourage, influence, advise or in any way participate in any partnership, limited partnership, syndicate or other
group, including, without limitation, any “group” (within the meaning of Section 13(d)(3) of the Exchange Act) with
respect to any Voting Securities or otherwise in any manner agree, attempt, seek or propose to deposit any Voting Securities into
any voting trust or subject any Voting Securities to any voting or similar arrangement, other than solely with other members of
the Investor Group and the Nominee;

 

		(ii)	(A) make, or in any way encourage or participate in any “solicitation” of “proxies”
(as such terms are used in the proxy rules of the SEC but without regard to the exclusion set forth in Rule 14a−1(l)(2)(iv)
under the Exchange Act) or consents to vote, or seek to advise, encourage or influence any Person with respect to the voting of,
any Voting Securities; or (B) otherwise communicate with the Company’s stockholders or others pursuant to Rule 14a−1(l)(2)(iv)
under the Exchange Act or otherwise regarding the Board, the Company, or the management, policies, strategies, affairs or business
of the Company;

 

		(iii)	(A) initiate, propose or otherwise “solicit” (as such terms are used in the proxy rules
of the SEC) stockholders of the Company for the approval of any stockholder proposal or cause or encourage any Person to initiate
any such stockholder proposal; (B) seek to call, or request the call of, or call a special meeting of the stockholders of the Company;
or (C) make a request for a list of the Company’s stockholders or other Company records;

 

		(iv)	support or participate in any “withhold the vote” or similar campaign with respect
to the Company or the Board, or seek election or appointment to, or representation on, or nominate or propose the nomination of
any candidate to the Board, including any nomination of any candidate to stand for election to the Board at the 2016 Meeting, other
than the Nominee (including any replacements designated in accordance with this Agreement) or the Company Nominees (including any
replacements designated in accordance with this Agreement); or seek the removal of any member of the Board;

 

		(v)	otherwise take, or make any public disclosure, announcement or statement (including, without limitation,
the filing of any document or report with the SEC or any other governmental agency or any disclosure to any journalist, member
of the media or securities analyst) with respect to any intention, plan or arrangement to take (or in support of any intention,
plan or arrangement of a third party to take), any action that is inconsistent with, any provision of this Agreement;

 

    	 	8	 

     

    

 

		(vi)	enter into any affirmative discussions or communications, or enter into any arrangement, understanding
or agreements (whether written or oral) with, or encourage, advise, assist, finance or facilitate, any Person in connection with
any of the foregoing, or make any investment in or enter into any arrangement with any other Person that engages, or offers or
proposes to engage, in any of the foregoing; or

 

		(vii)	otherwise take, or solicit, cause or encourage others to take, any action that would not be permitted
by any of the foregoing.

 

		(c)	Nothing in this Section 4.1 shall limit any actions that may be taken by the Nominee
acting solely as a director of the Company consistent with his fiduciary duties as a director to the Company’s stockholders.

 

		(d)	Nothing in this Agreement shall prohibit or restrict the Investor Group from taking any action
necessary to comply with any law, rule or regulation or any action required by any governmental or regulatory authority or stock
exchange that has, or may have, jurisdiction over the Investor Group or any of its Affiliates or Associates; provided, that
a breach by the Investor Group of this Agreement is not the cause of the applicable requirement.

 

		4.2	Covenants of the Company

 

		(a)	Subject to the terms and conditions set forth in this Agreement, the Company acknowledges and agrees,
so long as (i) none of the Investor, the Investor Affiliate, or any of their respective Affiliates or Associates, beneficially
owns more than 19.9% of the outstanding shares of Common Stock and (ii) any acquisition of Common Stock by the Investor, the Investor
Affiliate, or any of their respective Affiliates or Associates would reasonably be expected to actually limit Company’s ability
to utilize the NOLs, that none of Investor, Investor Affiliate, or any of their respective Affiliates or Associates shall be deemed
to be an “Acquiring Person” (as defined in the Plan), or any corollary provision in any Charter Amendment adopted by
the Company’s stockholders after the date of this Agreement.

 

		(b)	Notwithstanding anything to the contrary in this Agreement, if, at any time, the Board reasonably
determines that any acquisition of additional Common Stock by the Investor, the Investor Affiliate, or any of their respective
Affiliates or Associates would reasonably be expected to actually limit the Company’s ability to utilize the NOLs, then following
written notice delivered by the Board to the Investor (the “Waiver Termination Notice”) (i) Section 4.2(a) of
this Agreement and the waiver contemplated thereby shall not apply to any acquisition of any additional shares of Common Stock
by the Investor, the Investor Affiliate, or any of their respective Affiliates or Associates and (ii) the Investor and the Investor
Affiliate shall, and shall cause any of their respective Affiliates and Associates to, promptly cease any acquisition of any additional
shares of Common Stock of the Company, in each case, following the Investor’s receipt of such Waiver Termination Notice;
provided, however, that the Investor, the Investor Affiliate, and any of their respective Affiliates or Associates
shall nonetheless be permitted to acquire ownership of shares of Common Stock as a result of the exercise or assignment of any
option contracts that were entered into and disclosed to the Company, in writing (including pursuant to the Investors’ Section
13D filings) or through electronic mail to an individual designated by the Company, prior to the date that the Investor received
the Waiver Termination Notice.

 

    	 	9	 

     

    

 

		4.3	Non-Disparagement

 

Until the Termination
Date, neither the Company and its officers, directors or Affiliates, on the one hand, nor any of the Investor Group and their respective
officers, directors or Affiliates, on the other hand, shall directly or indirectly make or issue or cause to be made or issued
any disclosure, announcement, or statement (including the filing of any document or report with the SEC or any other governmental
agency unless required by law or the rules of any securities exchange on which the Common Stock is listed or traded and any disclosure
to any journalist, member of the media, or securities analyst) concerning the other party or any of its respective past, present
or future directors, director nominees, officers, members, employees, advisors or other Affiliates, which disparages such other
party or any of such other party’s respective past, present, or future directors, director nominees, officers, members, employees,
advisors or other Affiliates Associates. The restrictions in this Section 4.3 shall not apply in any compelled testimony
or production of information, either by legal process, subpoena or as part of a response to a request for information from any
governmental authority with jurisdiction over the party from whom information is sought to the extent legally required; provided,
however, that the recipient of such legal process, subpoena, or request shall promptly notify the other parties hereto of
the receipt of such legal process, subpoena or request so that such other parties may seek an appropriate protective order or other
remedy and the recipient shall reasonably cooperate in connection therewith.

 

		4.4	Confidential Information and Other Related Matters

 

Each of the Investor and the Investor Affiliate
acknowledges and agrees that the Nominee has received a copy of the Trading Policy and shall use good faith efforts to cause the
Nominee to:

 

		(a)	comply with the terms of such policy, which will restrict each Nominee from disclosing confidential
information regarding the Company to the Investor and the Investor Affiliate; and

 

		(b)	keep confidential and not disclose discussions and matters considered in meetings of the Board
and Board committees, unless previously disclosed publicly by the Company.

 

		4.5	Public Announcements and Securities Filings

 

		(a)	The Company shall announce this Agreement and the material terms hereof by a press release in the
form attached hereto as Exhibit A (the “Press Release”) on, or as soon as practicable after, the date
hereof.

 

    	 	10	 

     

    

 

		(b)	The Investor, the Investor Affiliate and the Nominee shall promptly prepare and file an amendment
(the “13D Amendment”) to the Investor 13D, and any amendments thereto, reporting the entry into this Agreement
and amending applicable items to conform to its obligations hereunder. The 13D Amendment shall be consistent with the Press Release
and the terms of this Agreement. The Investor and the Investor Affiliate shall provide the Company with reasonable opportunity
to review and comment upon the 13D Amendment prior to filing, and shall consider in good faith any changes proposed by the Company.

 

		(c)	The Company shall promptly prepare and file a Current Report on Form 8-K (the “Form 8-K”)
reporting the entry into this Agreement. The Form 8-K shall be consistent with the Press Release and the terms of this Agreement.
The Company shall provide the Investor with reasonable opportunity to review and comment upon the Form 8-K prior to filing, and
shall consider in good faith any changes proposed by the Investor.

 

ARTICLE
5

GENERAL

 

		5.1	Notices

 

All notices, requests,
claims, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given to a party if
delivered in person or sent by overnight delivery (providing proof of delivery) to the party at the following addresses (or at
such other address for a party as shall be specified by like notice) on the date of delivery, or if by facsimile, upon confirmation
of receipt:

 

		If to the Company:	Concurrent Computer Corporation

4375 River Green Parkway, Suite 100

Duluth, Georgia 30096

Attention: Executive Vice President

Facsimile: (678) 258-3933

 

		If to any member of
the Investor Group:	JDS1, LLC
2200 Fletcher Avenue, Suite 501

Fort
Lee, New Jersey 07024-5016

Attention:
Julian Singer

 

		5.2	No Third-Party Beneficiaries

 

Nothing in this Agreement,
whether express or implied, is intended to or shall confer any rights, benefits or remedies under or by reason of this Agreement
on any Persons other than the parties and their respective successors (it being understood in the case of the death of the Nominee,
his heirs, administrators, executors and personal representatives shall have no such rights, benefits or remedies but shall be
subject to any confidentiality or non-disclosure obligations that would have been applicable to the Nominee in the absence of his
death) and permitted assigns, nor is anything in this Agreement intended to relieve or discharge the obligation or liability of
any third Persons to any party, nor shall any provisions give any third Persons any right or subrogation over action against any
party.

 

    	 	11	 

     

    

 

		5.3	Securities Laws

 

Each of the Investor
and the Investor Affiliate acknowledge that the members of the Investor Group are aware and that the members of the Investor Group
have been advised that the federal securities laws prohibit any Person having non-public material information about a company from
purchasing or selling securities of that company.

 

		5.4	Communications

 

Except as may be otherwise
agreed with the Company from time to time, no members of the Investor Group (other than the Nominee to the extent acting in his
capacity as a member of the Board consistent with his fiduciary duties as a director to the Company’s stockholders) will
initiate or cause to be initiated (other than through members of the Board, the Company’s Chief Executive Officer, the Company’s
Chief Financial Officer, the Company’s General Counsel or such other Person(s) as the Company may designate in writing) any
communication relating to the business of the Company or its Affiliates, in each case, with any officer, director or employee of
the Company or any of its Affiliates.

 

		5.5	Governing Law

 

This Agreement shall
be governed and construed in accordance with the laws of the State of Delaware, without regard to the conflict of law principles
thereof. The parties and their respective Affiliates and Associates: (a) irrevocably and unconditionally consent and submit
to the jurisdiction of the Court of Chancery of the State of Delaware for purposes of any action, suit or proceeding arising out
of or relating to this Agreement; (b) agree that service of any process, summons, notice or document by U.S. registered mail
to the address set forth at the end of this Agreement shall be effective service of process for any action, suit or proceeding
brought against them; (c) irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or
proceeding arising out of or relating to this Agreement in the Court of Chancery of the State of Delaware; and (d) irrevocably
and unconditionally waive the right to plead or claim, and irrevocably and unconditionally agree not to plead or claim, that any
action, suit or proceeding arising out of or relating to this Agreement that is brought in the Court of Chancery of the State of
Delaware has been brought in an inconvenient forum.

 

		5.6	Fees and Expenses

 

The Company shall pay (or shall reimburse
the Investor and the Investor Affiliate for) the reasonably documented fees and expenses in an amount not to exceed $235,000 incurred
by the Investor and the Investor Affiliate as of the date of this Agreement in connection with the negotiation, execution and delivery
of this Agreement and the circumstances giving rise hereto, and paid or payable to third parties. Except as set forth in the preceding
sentence, each party shall bear all fees and expenses incurred by such party in connection with this Agreement and no party shall
seek or be entitled to reimbursement of any such fees and expenses from the other party.

 

    	 	12	 

     

    

 

		5.7	Assignment; Successors

 

This Agreement shall
be binding upon and inure to the benefit of and be enforceable by the parties and their respective successors (except, in the case
of the Nominee, as provided in Section 5.2). Without the consent of the Investor in the case of an assignment or delegation
by the Company, and without the consent of the Company in the case of an assignment or delegation by a member of the Investor Group,
no party to this Agreement may assign its rights or delegate its obligations under this Agreement, whether by operation of law
or otherwise.

 

		5.8	Amendments; Waivers

 

Subject to applicable
law, this Agreement may only be amended pursuant to a written agreement executed by all the parties, and no waiver of compliance
with any provision or condition of this Agreement and no consent provided for in this Agreement shall be effective unless evidenced
by a written instrument executed by the party against whom such waiver or consent is to be effective. No failure or delay by a
party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial
exercise thereof preclude any other or further exercise thereof or the exercise of any right, power or privilege hereunder.

 

		5.9	Entire Agreement

 

This Agreement constitutes
the entire agreement of all the parties and supersedes any and all prior and contemporaneous agreements, memoranda, arrangements
and understandings, both written and oral, between the parties, or any of them, with respect to the subject matter hereof. No representation,
warranty, promise, inducement or statement of intention has been made by any party which is not contained in this Agreement and
no party shall be bound by, or be liable for, any alleged representation, promise, inducement or statement of intention not contained
herein or therein. The parties expressly disclaim reliance on any information, statements, representations or warranties regarding
the subject matter of this Agreement other than the terms of this Agreement.

 

		5.10	Counterparts

 

To facilitate execution,
this Agreement may be executed in any number of counterparts (including by facsimile transmission or e-mail), each of which shall
be deemed to be an original, but all of which together shall constitute one binding agreement on the parties, notwithstanding that
not all parties are signatories to the same counterpart.

 

		5.11	Captions

 

The captions contained
in this Agreement are for convenience only and shall not affect the construction or interpretation of any provisions of this Agreement.

 

    	 	13	 

     

    

 

		5.12	Specific Performance

 

The parties agree that
irreparable damage would occur in the event any of the provisions of this Agreement were not performed in accordance with the terms
hereof and that the parties are entitled to an injunction or specific performance of the terms hereof in addition to any other
remedies at law or in equity.

 

		5.13	Termination

 

This Agreement and
the provisions herein shall remain in full force and effect until the earliest to occur of (such date, the “Termination
Date”):

 

(a) (i) fifteen (15)
business days prior to the deadline for the submission of stockholder nominations of directors and business proposals for the 2017
Meeting pursuant to the Company’s Amended and Restated Bylaws, and (ii) if the 2017 Meeting is not held prior to the first anniversary
of the 2016 Meeting (the “Outside Date”), then the date that, but for the Company’s failure to hold the
2017 Meeting by the Outside Date, would have been fifteen (15) business days prior to the expiration of the Company’s deadline
for the submission of stockholder nominations of directors and business proposals pursuant to the Company’s Amended and Restated
Bylaws with respect to the 2017 Meeting had the 2017 Meeting occurred on the Outside Date;

 

(b) a material breach
of this Agreement by the Company, the Board or the Investor Group, provided that the non-breaching party elects in writing to terminate
this Agreement (the date of such election of termination being the Termination Date);

 

(c) receipt of written
notice from the Board to the Investor (which notice shall be given in the discretion of the Board) that the members of the Investor
Group, collectively, have ceased to beneficially own, in the aggregate, at least 7.5% of the outstanding Voting Securities and
the Board desires to terminate this Agreement; or

 

(d) such other date
established by mutual written agreement of the Parties hereto.

 

Notwithstanding the
foregoing, the provisions of Section 4.2 and this Article 5 shall survive the termination of this Agreement.

 

		5.14	Severability.

 

If any term, provision,
covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the
remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall
in no way be affected, impaired or invalidated. The parties agree to use their commercially reasonable best efforts to agree upon
and substitute a valid and enforceable term, provision, covenant or restriction for any of such that is held invalid, void or enforceable
by a court of competent jurisdiction.

 

* * * * *

 

    	 	14	 

     

    

 

IN WITNESS WHEREOF,
the parties have duly executed this Agreement as of the date first above written.

 

 

 

	 	Concurrent Computer Corporation	 
	 	 	 
	 	 	 
	 	By: 	/s/ Derek Elder	 
	 	 	Name: Derek Elder
Title: President and Chief Executive Officer	 
	 	 	 	 
	 	 	 	 
	 	JDS1, LLC	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Julian Singer	 
	 	 	Name: Julian Singer
Title: Manager	 
	 	 	 	 
	 	 	 	 
	 	Julian Singer	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Julian Singer	 
	 	 	 	 

 

    	 	Signature Page to Board Representation and Standstill Agreement	 

     

    

 

	 	 	 
	 	   	NOMINEE:	 
	 	 	 	 
	 	 	 	 
	 	 	/s/ Wayne Barr	 
	 	 	By: Wayne Barr	 

 

    	 	Signature Page to Board Representation and Standstill Agreement	 

     

    

 

Schedule A

 

Shares of Common Stock Beneficially Owned
by the Investor Group

 

	JDS1, LLC	894,536
	 	 
	Julian Singer	894,536

 

 

The Investor has sold 325 Put Contracts
as of the date hereof:

 

	Nature of the Transaction	Put Options Purchased /
    (Sold)1
	Sale of Put Options	(200) CCUR Put Contracts@$5;9/16/16
(Sell)
	Sale of Put Options	(25) CCUR Put Contracts@$5;9/16/16
(Sell)
	Sale of Put Options	(100) CCUR Put Contracts@$5;9/16/16
(Sell)

 

 

 

		1	Each Put Contract relates
to 100 shares of Common Stock.

 

    	 	 	 

     

    

 

Exhibit A

 

Press Release

 

    	 	 	 

     

    

 

 

FOR IMMEDIATE RELEASE

 

Concurrent’s Appointment of Directors

 

ATLANTA, GA – August 29, 2016 – Concurrent
(NASDAQ: CCUR), a global provider of high-performance Linux® and storage solutions, today announced that it has reached an
agreement under which Wayne Barr will join Concurrent’s Board of Directors. This agreement was reached between the Company
and JDS1, LLC and Julian Singer, beneficial owners of the Company’s common stock. Under the terms of the agreement:

 

		·	JDS1, LLC and Julian Singer, as beneficial owners, will vote their
shares in favor the Company’s slate of board nominees at the Company’s 2016 Annual Meeting of Stockholders.

 

		·	C. Shelton James has resigned from the Board and the Board has appointed
Wayne Barr to serve as a new director for a term that expires at the 2016 Annual Meeting of Stockholders.

 

		·	The Board will nominate Wayne Barr for election as a director of the
Company together with Steve Nussrallah, Derek Elder, Charles Blackmon, Larry Enterline, Dilip Singh, and Robert Pons and will recommend
in favor of their election by stockholders at the 2016 Annual Meeting of Stockholders.

 

Mr. Barr has extensive experience in the telecommunications,
technology, and real estate sectors, currently working as the managing director of full-service real estate firm, Alliance Group
of NC, LLC, as well as the principal at Oakleaf Consulting Group, which he founded in 2001. Mr. Barr co-founded and worked as the
president of Capital & Technology Advisors and has held board memberships at numerous companies, including Anacomp, Leap Wireless
International, NEON Communications, Globix Corporation, and nanotechnology company Evident Technologies. Since January 2014, Barr
has been a director of public financial and diversified holding company HC2 Holdings (NYSE: HCHC).

 

Steve G. Nussrallah, Chairman of the Board, stated, “On
behalf of the entire Concurrent board, I would like to thank Mr. James for his time, dedication and invaluable contributions to
Concurrent. He has been an asset to our company and he will be genuinely missed. We are also pleased that Mr. Barr is joining the
Concurrent board. Mr. Barr brings to Concurrent a broad range of experience and knowledge and we are confident that he will be
a great contributor to the Company.”

 

    	 	 	 

     

    

 

In connection with the appointment of Mr. Barr to the Board,
the Company has entered into a customary standstill agreement with JDS1, LLC and Julian Singer. Details of this agreement can be
found in Concurrent’s 8-K filed today with the U.S. Securities and Exchange Commission.

 

About Concurrent

 

Concurrent (NASDAQ: CCUR) is a global software and solutions
company that develops advanced applications on a core foundation of high-performance Linux and storage technologies. We serve industries
and customers that demand uncompromising performance, reliability and flexibility to gain a competitive edge, drive meaningful
growth and confidently deliver best-in-class solutions that enrich the lives of millions of people around the world every day. Offices
are located in North America, Europe and Asia. Visit www.concurrent.com for further
information and follow us on Twitter: www.twitter.com/Concurrent_CCUR.

 

Certain statements made or incorporated by reference in this
release may constitute “forward-looking statements” within the meaning of the federal securities laws. Statements regarding
future events and developments, including, but not limited to, Concurrent’s intent to recommend in favor of the election
of the slate of directors described above at the 2016 Annual Meeting of Stockholders, are forward-looking statements within the
meaning of these laws. All forward-looking statements are subject to certain risks and uncertainties that could cause actual events
to differ materially from those projected.

 

Some of these risks and uncertainties include, without limitation:
changes in the value, character or nature of Concurrent’s net operating loss carryforwards; the potential consolidation of
the markets that we serve, U.S. government sequestration; European austerity measures; delays or cancellations of customer orders;
non-renewal of maintenance and support service agreements with customers; changes in product demand; economic conditions; various
inventory risks due to changes in market conditions; margins of video solutions business to capture new business; fluctuations
and timing of large video solutions orders; doing business in the People’s Republic of China; uncertainties relating to the development
and ownership of intellectual property; uncertainties relating to our ability and the ability of other companies to enforce their
intellectual property rights; the pricing and availability of equipment, materials and inventories; the concentration of our customers;
failure to effectively manage change; delays in testing and introductions of new products; the impact of reductions in force on
our operations; rapid technology changes; system errors or failures; reliance on a limited number of suppliers and failure of components
provide by those suppliers; uncertainties associated with international business activities, including foreign regulations, trade
controls, taxes, and currency fluctuations; the impact of competition on the pricing of video solutions products; failure to effectively
service the installed base; the entry of new well-capitalized competitors into our markets; the success of new video solutions;
the success of our relationships with technology and channel partners; capital spending patterns by a limited customer base; the
current challenging macroeconomic environment; continuing unevenness of the global economic recovery; privacy concerns over data
collection; our ability to utilize net operating losses to offset cash taxes in the event of an ownership change as defined by
the Internal Revenue Service; earthquakes, tsunamis, floods and other natural disasters in areas in which our customers and suppliers
operate; and the availability of debt or equity financing to support our liquidity needs.

 

    	 	 	 

     

    

 

Other important risk factors are discussed
in Concurrent’s Form 10-K filed August 26, 2015 with the Securities and Exchange Commission (“SEC”), and in subsequent
filings of periodic reports with the SEC. The risk factors discussed in the Form 10-K and subsequently filed periodic reports under
the heading “Risk Factors” are specifically incorporated by reference in this press release. Forward-looking statements
are based on current expectations and speak only as of the date of such statements. Concurrent undertakes no obligation to publicly
update or revise any forward-looking statement, whether as a result of future events, new information, or otherwise.

 

# # #

 

Concurrent Computer Corporation and its logo are registered
trademarks of Concurrent. All Concurrent product names are trademarks or registered trademarks of Concurrent while all other
product names are trademarks or registered trademarks of their respective owners.

 

For more information, contact:

 

Media Relations:

Tom Williams

Phone: (678) 258-4059

Email: tom.williams@ccur.com

 

Investor Relations:

ICR

Seth Potter

Phone: (646) 277-1230

Email: Seth.Potter@icrinc.comExhibit

Exhibit 10.40

October 6, 2014

Mr. Steven Fasman
2 Griffen Drive
Larchmont, New York, 10538

Dear Steven:

Congratulations on your offer of employment!  Catalent is the leading provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products.  We take great pride in hiring executives who have talent, drive and commitment, and we are extremely delighted to have you join our team.

Attached is important information about our organization, your individual position, benefits and rewards. I encourage you to thoroughly review all materials and contact me with questions. 

I am pleased to confirm in writing our offer of employment to you. The major provisions of your offer are:

		
	1.
	Position:  Your position is Senior Vice President and General Counsel reporting directly to me.  As the Senior Vice President and General Counsel, you will also be a member of Catalent’s Executive Leadership Team and will be located at our Somerset, NJ office.

		
	2.
	Pay:  Your base bi-weekly rate of pay will be $19,230.77 (annualized to $500,000.00).  The official Catalent workweek starts on Monday and runs through Sunday.  Catalent employees are paid every other Friday, one week in arrears according to the payroll schedule included in your packet. 

		
	3.
	Performance:  Your performance and merit reviews will follow the standard annual review calendar for Catalent. 

		
	4.
	Rewards:  Catalent is pleased to offer a comprehensive, competitive compensation program that rewards talented employees for their performance. 

		
	a.
	You will be eligible for participation in our short-term incentive plan, which we call our Management Incentive Plan (MIP). Your target incentive for fiscal year 2015 (July 1, 2014 - June 30, 2015) will be 75% of your annual base salary.  Annual bonus payments are determined based upon the achievement of specific financial and management objectives. This will be explained to you in more detail when you come on board, but I am glad to answer any questions you may have in the interim.  

		
	b.
	You will be eligible for our health, life, disability and 401(k) retirement savings plans on your first day of employment. You will receive more information on these benefits during your new hire orientation.

		
	c.
	You will be eligible to participate in Catalent’s Deferred Compensation Plan that enables you to save over the IRS limits in the qualified 401(k) plan.  Complete details on the features of this plan and how to enroll will be mailed to your home.

		
	d.
	In recognition of your leadership position, you will be recommended to receive an annual Long-Term Incentive Plan (LTIP) Grant equal to 100% of your base salary. Since LTIP grants have equity components, your grant 

is subject to the approval of the Compensation Committee of Catalent’s Board of Directors. The Committee meets various times during each fiscal year. The complete terms and conditions of the Plan, including the equity components and related award agreements, which contain certain restrictive covenants, will be provided to you once the grant has been approved.  

		
	e.
	The Total Direct Compensation which includes your base salary, annual Management Incentive Plan bonus at Target and annual Long Term Incentive grant at Target is $1.375m.

		
	5.
	Severance:   A separate severance agreement letter will be provided to you to reflect a severance benefit equal to your annual base salary and MIP target bonus subject to the terms of the agreement.  

6.  Paid Time Off:  Upon joining Catalent you will receive seven (7) paid company holidays (New Years Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day and the day following, and Christmas Day).  You will also be eligible to receive up to 26 days of PTO each year. For 2014, this will be prorated based upon your start date. PTO includes vacation, sick and personal days, all of which need to be used during the 2014 calendar year as we do not permit carry over, unless lawfully required.  

7. Screening: The company paid drug screen must be completed within three business days of acceptance of this offer, with acceptable results.  A chain of custody form, required for your drug screen, will be sent to you via e-mail by our vendor with information on how to complete the drug screen.  The e-mail will also contain contact information for the nearest testing facility to your home address.  Be sure to bring a printed copy of the e-mail along with a government issued photo ID to the facility in order to process your drug screen.

8.  Terms:  Notwithstanding anything to the contrary herein, employment with Catalent is not for any definite period of time and is terminable, with or without notice, at the will of either you or the company at any time for any reason. There shall be no contract, express or implied, of employment.

		
	9.
	Confidentiality:  Catalent does not hire people for the purpose of acquiring their current or former employer’s trade secrets, intellectual property, or other confidential or proprietary information, and Catalent does not want access to any materials containing such information.  Consequently, any documents, computer discs, etc. containing any such information should be returned to your current or former employer, and in no case may such information be brought to, or used, at Catalent.

		
	10.
	Ethics:  As a company founded on a core set of values, you will be provided with Catalent’s Standards of Business Conduct and be prepared to sign a letter of compliance.  You also represent that there is nothing that will prevent you from performing the role and duties commensurate of Senior Vice President and General Counsel with global responsibilities.

		
	11.
	Orientation:  Orientation for new hires is conducted monthly at the Somerset facility.  We will work out a mutually agreeable day and time for your orientation to receive information about the benefits program, as well as technology training.  The Immigration Reform and Control Act of 1986 require employers to verify the employment eligibility and identity of all new employees.  In accordance with this Act, please bring the appropriate identifying documents with you on your first day of employment.  A sample copy of the I-9 form including a list of accepted documentation of proof of work authorization is attached in this offer packet for your review.  You do not need to complete this form now, but will be asked to complete it on your first day of employment. Typical identification items include your driver’s license and social security card. 

		
	12.
	Start Date:  Your first day of employment will be October 14, 2014.

Your agreement to the terms of this letter supersedes any other oral or written agreement or understanding you have with the Company (including any predecessor entity) regarding your eligibility for rewards and benefits.  As mentioned above, please scan and email a signed copy of this offer to Anna Murray at anna.murray@catalent.com.  Please sign 

below your agreement to the terms of this letter.  If you have any questions, please feel free to call me at 732-537-6401 or Lance Miyamoto at 732-537-6147.

We look forward to you joining the team!

Sincerely,

John Chiminski
President and Chief Executive Officer,
Catalent Pharma Solutions, Inc.

Enclosures                     
                
cc:  Lance Miyamoto

I accept the above offer of employment: 

__________________________________________________    __________________ 
Steven Fasman                            Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]